In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Metabolic syndrome: assessment of endothelial dysfunction and degree of apoptosis

Session Poster Session III - Friday 08:30 - 12:30


Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Obesity
  • Session type : Poster Session

Authors : TA Deeva (Moscow,RU), OM Drapkina (Moscow,RU), VT Ivashkin (Moscow,RU)

TA Deeva1 , OM Drapkina1 , VT Ivashkin1 , 1I.M. Sechenov First Moscow State Medical University, clinic of the internal disease - Moscow - Russian Federation ,


Aim: to evaluate endothelial dysfunction and the level of serum marker of apoptosis (caspase-8) in patients with metabolic syndrome (MetS).

Methods: The study included 76 patients: 43 patients with MetS, 33 patients without MetS (control group), the average age of 61±12 years. Assessment of endothelial dysfunction was performed using the photoplethysmography; the level of caspase-8 was investigated.

Results: The duration of systole in the group with MetS (ED%) was significantly higher than in control (p=0,037). Occlusion index and phase shift in basic group was significantly lower (1,43±0.44 and -6,14±5,7) in comparison with the control (1,68±0,6 and -2,65±7,69) respectively, p<0,05. A negative correlation has been identified between the index of occlusion and arterial hypertension, diastolic dysfunction, left ventricular hypertrophy, presence of coronary artery disease,?<0,05. An average level of caspase-8 in a group with MetS was significantly higher than in control (p=0,022). Positive correlation was revealed between the level of caspase-8 on the one hand and obesity (r=0,229)*, atherosclerosis of aorta (r=0,310)*, liver steatosis (r=0,462)* and pancreatic steatosis (r=0,354)*, nonalcoholic steatohepatitis (r=0,309)* on the other hand, *p<0,05.

Conclusions: In patients with MetS compared with the control group the following have been identified:
1) Increased duration of systolic function that can indicate a diastole time reduction, the deterioration of myocardial perfusion;
2) A higher frequency endothelial dysfunction occurrence in large muscular and small resistant arteries;
3) A higher level of caspase-8;
All the above can serve as a risk factor and prognostic marker of adverse development of cardiovascular and hepatobiliary diseases.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are